Clinical trial NCT04219358 - References

Actinic Cheilitis — Topical Application of Imiquimod Gel at Different Concentrations in Actinic Cheilitis

Citation(s)

•   A Gaspari A, Tyring SK, Rosen T
  Beyond a decade of 5% imiquimod topical therapy. J Drugs Dermatol. 2009 May;8(5):467-74. Review.
•   Bernardi A, Braganhol E, Jäger E, Figueiró F, Edelweiss MI, Pohlmann AR, Guterres SS, Battastini AM
  Indomethacin-loaded nanocapsules treatment reduces in vivo glioblastoma growth in a rat glioma model. Cancer Lett. 2009 Aug 18;281(1):53-63. doi: 10.1016/j.canlet.2009.02.018. Epub 2009 Mar 14.
•   Bernardi A, Frozza RL, Jäger E, Figueiró F, Bavaresco L, Salbego C, Pohlmann AR, Guterres SS, Battastini AM
  Selective cytotoxicity of indomethacin and indomethacin ethyl ester-loaded nanocapsules against glioma cell lines: an in vitro study. Eur J Pharmacol. 2008 May 31;586(1-3):24-34. doi: 10.1016/j.ejphar.2008.02.026. Epub 2008 Feb 19.
•   Bernardi A, Zilberstein AC, Jäger E, Campos MM, Morrone FB, Calixto JB, Pohlmann AR, Guterres SS, Battastini AM
  Effects of indomethacin-loaded nanocapsules in experimental models of inflammation in rats. Br J Pharmacol. 2009 Oct;158(4):1104-11. doi: 10.1111/j.1476-5381.2009.00244.x. Epub 2009 May 6.
•   Bulcão RP, de Freitas FA, Dallegrave E, Venturini CG, Baierle M, Durgante J, Sauer E, Cassini C, Cerski CT, Zielinsky P, Salvador M, Pohlmann AR, Guterres SS, Garcia SC
  In vivo toxicological evaluation of polymeric nanocapsules after intradermal administration. Eur J Pharm Biopharm. 2014 Feb;86(2):167-77. doi: 10.1016/j.ejpb.2013.04.001. Epub 2013 May 2.
•   Bulcão RP, Freitas FA, Venturini CG, Dallegrave E, Durgante J, Göethel G, Cerski CT, Zielinsky P, Pohlmann AR, Guterres SS, Garcia SC
  Acute and subchronic toxicity evaluation of poly(e-caprolactone) lipid-core nanocapsules in rats. Toxicol Sci. 2013 Mar;132(1):162-76. doi: 10.1093/toxsci/kfs334. Epub 2012 Dec 12.
•   Cataldo E, Doku HC
  Solar cheilitis. J Dermatol Surg Oncol. 1981 Dec;7(12):989-95.
•   Cavalcante AS, Anbinder AL, Carvalho YR
  Actinic cheilitis: clinical and histological features. J Oral Maxillofac Surg. 2008 Mar;66(3):498-503. doi: 10.1016/j.joms.2006.09.016.
•   Contri RV, Frank LA, Kaiser M, Pohlmann AR, Guterres SS
  The use of nanoencapsulation to decrease human skin irritation caused by capsaicinoids. Int J Nanomedicine. 2014 Feb 12;9:951-62. doi: 10.2147/IJN.S56579. eCollection 2014.
•   Contri RV, Katzer T, Ourique AF, da Silva AL, Beck RC, Pohlmann AR, Guterres SS
  Combined effect of polymeric nanocapsules and chitosan hydrogel on the increase of capsaicinoids adhesion to the skin surface. J Biomed Nanotechnol. 2014 May;10(5):820-30.
•   Couvreur P, Barratt G, Fattal E, Legrand P, Vauthier C
  Nanocapsule technology: a review. Crit Rev Ther Drug Carrier Syst. 2002;19(2):99-134. Review.
•   Daniel FI, Alves SR, Vieira DS, Biz MT, Daniel IW, Modolo F
  Immunohistochemical expression of DNA methyltransferases 1, 3a, and 3b in actinic cheilitis and lip squamous cell carcinomas. J Oral Pathol Med. 2016 Nov;45(10):774-779. doi: 10.1111/jop.12453. Epub 2016 May 9.
•   de Souza Lucena EE, Costa DC, da Silveira EJ, Lima KC
  Prevalence and factors associated to actinic cheilitis in beach workers. Oral Dis. 2012 Sep;18(6):575-9. doi: 10.1111/j.1601-0825.2012.01910.x. Epub 2012 Feb 15.
•   dos Santos LR, Cernea CR, Kowalski LP, Carneiro PC, Soto MN, Nishio S, Hojaij FC, Dutra Júnior A, Britto e Silva Filho G, Ferraz AR
  Squamous-cell carcinoma of the lower lip: a retrospective study of 58 patients. Sao Paulo Med J. 1996 Mar-Apr;114(2):1117-26.
•   Dufresne RG Jr, Curlin MU
  Actinic cheilitis. A treatment review. Dermatol Surg. 1997 Jan;23(1):15-21. Review.
•   Eigentler TK, Kamin A, Weide BM, Breuninger H, Caroli UM, Möhrle M, Radny P, Garbe C
  A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. J Am Acad Dermatol. 2007 Oct;57(4):616-21. Epub 2007 Jul 3.
•   Falagas ME, Angelousi AG, Peppas G
  Imiquimod for the treatment of actinic keratosis: A meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2006 Sep;55(3):537-8.
•   Ferreira AM, de Souza Lucena EE, de Oliveira TC, da Silveira É, de Oliveira PT, de Lima KC
  Prevalence and factors associated with oral potentially malignant disorders in Brazil's rural workers. Oral Dis. 2016 Sep;22(6):536-42. doi: 10.1111/odi.12488. Epub 2016 May 17.
•   Frank LA, Chaves PS, D'Amore CM, Contri RV, Frank AG, Beck RC, Pohlmann AR, Buffon A, Guterres SS
  The use of chitosan as cationic coating or gel vehicle for polymeric nanocapsules: Increasing penetration and adhesion of imiquimod in vaginal tissue. Eur J Pharm Biopharm. 2017 May;114:202-212. doi: 10.1016/j.ejpb.2017.01.021. Epub 2017 Feb 1.
•   Frank LA, Sandri G, D'Autilia F, Contri RV, Bonferoni MC, Caramella C, Frank AG, Pohlmann AR, Guterres SS
  Chitosan gel containing polymeric nanocapsules: a new formulation for vaginal drug delivery. Int J Nanomedicine. 2014 Jun 28;9:3151-61. doi: 10.2147/IJN.S62599. eCollection 2014.
•   Gebauer K, Shumack S, Cowen PS
  Effect of dosing frequency on the safety and efficacy of imiquimod 5% cream for treatment of actinic keratosis on the forearms and hands: a phase II, randomized placebo-controlled trial. Br J Dermatol. 2009 Oct;161(4):897-903. doi: 10.1111/j.1365-2133.2009.09260.x. Epub 2009 May 26.
•   Greenberg HL, Cohen JL, Rosen T, Orengo I
  Severe reaction to 5% imiquimod cream with excellent clinical and cosmetic outcomes. J Drugs Dermatol. 2007 Apr;6(4):452-8.
•   Jorizzo J, Dinehart S, Matheson R, Moore JK, Ling M, Fox TL, McRae S, Fielder S, Lee JH
  Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. J Am Acad Dermatol. 2007 Aug;57(2):265-8. Epub 2007 May 18.
•   Kaugars GE, Pillion T, Svirsky JA, Page DG, Burns JC, Abbey LM
  Actinic cheilitis: a review of 152 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999 Aug;88(2):181-6.
•   Kopera D, Kerl H
  Visualization and treatment of subclinical actinic keratoses with topical imiquimod 5% cream: an observational study. Biomed Res Int. 2014;2014:135916. doi: 10.1155/2014/135916. Epub 2014 May 11.
•   Krawtchenko N, Roewert-Huber J, Ulrich M, Mann I, Sterry W, Stockfleth E
  A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol. 2007 Dec;157 Suppl 2:34-40.
•   Lebwohl M, Dinehart S, Whiting D, Lee PK, Tawfik N, Jorizzo J, Lee JH, Fox TL
  Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol. 2004 May;50(5):714-21.
•   Lundeen RC, Langlais RP, Terezhalmy GT
  Sunscreen protection for lip mucosa: a review and update. J Am Dent Assoc. 1985 Oct;111(4):617-21.
•   Manganaro AM, Will MJ, Poulos E
  Actinic cheilitis: a premalignant condition. Gen Dent. 1997 Sep-Oct;45(5):492-4.
•   McDonald C, Laverick S, Fleming CJ, White SJ
  Treatment of actinic cheilitis with imiquimod 5% and a retractor on the lower lip: clinical and histological outcomes in 5 patients. Br J Oral Maxillofac Surg. 2010 Sep;48(6):473-6. doi: 10.1016/j.bjoms.2009.08.024.
•   Poitevin NA, Rodrigues MS, Weigert KL, Macedo CLR, Dos Santos RB
  Actinic cheilitis: proposition and reproducibility of a clinical criterion. BDJ Open. 2017 Aug 4;3:17016. doi: 10.1038/bdjopen.2017.16. eCollection 2017.
•   Smith KJ, Germain M, Yeager J, Skelton H
  Topical 5% imiquimod for the therapy of actinic cheilitis. J Am Acad Dermatol. 2002 Oct;47(4):497-501.
•   Sotiriou E, Lallas A, Goussi C, Apalla Z, Trigoni A, Chovarda E, Ioannides D
  Sequential use of photodynamic therapy and imiquimod 5% cream for the treatment of actinic cheilitis: a 12-month follow-up study. Br J Dermatol. 2011 Oct;165(4):888-92. doi: 10.1111/j.1365-2133.2011.10478.x. Epub 2011 Sep 15.
•   Spyridonos P, Gaitanis G, Tzaphlidou M, Bassukas ID
  Spatial fuzzy c-means algorithm with adaptive fuzzy exponent selection for robust vermilion border detection in healthy and diseased lower lips. Comput Methods Programs Biomed. 2014 May;114(3):291-301. doi: 10.1016/j.cmpb.2014.02.017. Epub 2014 Mar 6.
•   Swanson N, Abramovits W, Berman B, Kulp J, Rigel DS, Levy S
  Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles. J Am Acad Dermatol. 2010 Apr;62(4):582-90. doi: 10.1016/j.jaad.2009.07.004. Epub 2010 Feb 4.

Evaluation of Topical Application of 5% Imiquimod, 0.05% Imiquimod and 0.05% Nanoencapsulated Imiquimod Gel in the Treatment of Actinic Cheilitis: a Randomized Controlled Trial

Details for clinical trial NCT04219358